By Isnaini Azizah 
The landscape of modern telehealth is undergoing a seismic shift as Hims & Hers Health, a company once synonymous with direct-to-consumer lifestyle medications, prepares to anchor its future in the burgeoning and controversial world of peptide therapies. Shares of the San Francisco-based telehealth giant experienced a significant surge on Thursday, a direct response to a pivotal announcement from Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. The Secretary revealed that the Food and Drug Administration (FDA) is slated to convene a Pharmacy Compounding Advisory Committee (PCAC) meeting specifically to evaluate a suite of peptides for potential inclusion on the 503A bulk substances list. This regulatory move, if successful, would grant compounding pharmacies the legal authority to create individualized peptide prescriptions from bulk ingredients, effectively moving these substances from the fringes of the "gray market" into the mainstream of regulated American medicine.
For Hims & Hers, the timing of this regulatory thaw is critical. The company has spent the last year navigating the high-margin but volatile market of compounded GLP-1 medications, such as semaglutide and tirzepatide. While these weight-loss drugs have driven record revenues, they exist in a precarious regulatory environment tied to drug shortages. As manufacturers like Novo Nordisk and Eli Lilly ramp up production to resolve these shortages, the legal window for compounding branded GLP-1s may narrow. Consequently, Hims & Hers is aggressively diversifying its portfolio, positioning peptides not merely as a secondary offering, but as the next major growth engine for its digital health platform.
Peptides are essentially short chains of amino acids, the fundamental building blocks of proteins. In the medical and wellness communities, they are lauded for their ability to signal specific biological processes, ranging from muscle repair and fat loss to cognitive enhancement and skin rejuvenation. However, they remain a flashpoint of controversy. Critics and traditional medical bodies often point to a lack of robust, long-term clinical data regarding their safety and efficacy. Until recently, many of these substances were relegated to "research chemical" websites, sold with labels warning against human consumption to bypass FDA oversight. The current administration’s push to review these substances suggests a radical departure from the Biden-era FDA, which had previously moved to restrict peptide compounding, citing safety concerns.
The strategic pivot for Hims & Hers was solidified in February 2025, when the company finalized the acquisition of a specialized, California-based peptide manufacturing facility. This acquisition was not a reactive move but a calculated investment in vertical integration. At the time of the deal, CEO Andrew Dudum described the demand for peptides as a "future-facing innovation" that would allow the company to lead in categories that have yet to be fully realized by traditional healthcare providers. By owning the manufacturing process, Hims & Hers can ensure quality control and maintain high margins, even as it scales its operations to meet the demands of a consumer base increasingly obsessed with "biohacking" and longevity.
Following Secretary Kennedy’s announcement, Dr. Patrick Carroll, the Chief Medical Officer at Hims & Hers, emphasized the importance of bringing these therapies into a physician-led environment. Carroll argued that the goal is to provide a safe, regulated alternative to the unregulated market where many Americans currently seek these treatments. "Our medical team believes certain peptide therapies hold meaningful potential in helping Americans live healthier lives," Carroll stated, adding that the company is actively exploring how to expand access in a way that remains strictly aligned with forthcoming FDA guidance. This sentiment reflects a broader industry hope that the "gray market" for peptides can be dismantled and replaced by a transparent, prescription-based model facilitated by telehealth platforms.
Financial analysts are watching the situation with a mixture of optimism and caution. Michael Cherny, an analyst at Leerink Partners, noted that while the FDA’s review is a clear positive for Hims & Hers, the financial impact will not be instantaneous. Cherny, who maintains a hold-equivalent rating on the stock with a $25 price target, suggested that while peptides represent a clear growth avenue that Hims & Hers will likely "push hard on," the regulatory process is slow. The stock, which traded around $26 following the news, reflects investor confidence in the company’s ability to pivot, but the long-term valuation will depend on the FDA’s final decision regarding the 503A bulk list.
The list of peptides under consideration includes several high-profile substances that have gained a cult following in the wellness community. One of the most discussed is MK-677, also known as Ibutamoren. MK-677 is a growth hormone secretagogue that mimics the action of the hunger hormone ghrelin. While it is popular among athletes for its ability to increase lean muscle mass and improve sleep quality, it is also highly controversial. It has been banned by the World Anti-Doping Agency (WADA) and is often treated as an illicit substance when marketed for human use without a prescription. Its inclusion on the FDA’s review list is a bold signal from Secretary Kennedy, who has been a vocal critic of what he calls the "over-regulation" of alternative health treatments.
Other peptides on the list, such as GHK-Cu and Semax, carry less stigma but remain largely unproven by the standards of traditional Western medicine. GHK-Cu is a copper peptide frequently used in high-end skincare for its purported ability to stimulate collagen production and promote wound healing. Semax, a peptide developed in Russia, is often used as a nootropic for cognitive enhancement and neuroprotection. While these substances are generally viewed as lower-risk than growth hormone secretagogues, the lack of large-scale, double-blind clinical trials remains a hurdle for widespread medical acceptance.
The political dimension of this shift cannot be overstated. During a House Ways and Means Committee hearing on Thursday, Secretary Kennedy defended his stance on peptides, arguing that they were never intended to be heavily regulated in the first place. He characterized the previous administration’s restrictions as being based on "unfounded" safety concerns that stifled innovation and limited patient choice. Kennedy’s "Make America Healthy Again" (MAHA) agenda aligns closely with the interests of telehealth companies like Hims & Hers, which thrive on providing access to treatments that may be difficult to obtain through traditional primary care physicians.
The FDA’s Pharmacy Compounding Advisory Committee meeting, scheduled for July, will serve as an advisory body. While its recommendations are not legally binding, they carry significant weight in the FDA’s final rulemaking process. If the committee recommends the inclusion of these peptides on the 503A list, it would create a standardized legal framework for compounding pharmacies across the country. This would allow Hims & Hers to move beyond the "gray area" and market these therapies with the same level of confidence and scale they currently apply to their hair loss and erectile dysfunction products.
As Hims & Hers prepares for this potential new era, it faces the challenge of balancing rapid growth with clinical responsibility. The company’s platform relies on a network of licensed healthcare providers who must vet patients for these treatments. Expanding into peptides will require more rigorous screening and perhaps more frequent monitoring than the company’s existing product lines. The acquisition of the California facility suggests that Hims & Hers is ready to take on the complexities of sterile compounding, a process that requires much higher standards of cleanliness and precision than non-sterile products.
The shift toward peptides also signals a broader trend in the American healthcare system: the rise of "optimization medicine." Consumers are no longer satisfied with simply treating acute illnesses; they are looking for ways to optimize their physical and mental performance. Peptides, with their promise of targeted biological intervention, are the perfect product for this new consumer mindset. For Hims & Hers, the goal is to become the primary gateway for this movement, leveraging its user-friendly interface and national brand recognition to dominate a market that was once the exclusive domain of elite athletes and wealthy "biohackers."
While the road to full regulatory approval for peptide compounding is still long, the momentum is undeniably shifting. The combination of a friendly regulatory environment under Secretary Kennedy and the strategic infrastructure investments by Hims & Hers has created a unique window of opportunity. If the July FDA meeting results in a favorable outcome, Hims & Hers may find itself at the forefront of a multi-billion dollar industry, effectively replacing the temporary boost of GLP-1 compounding with a sustainable, long-term business model built on the next generation of protein-based medicine. Investors and patients alike will be watching closely as the FDA begins its formal review, a process that could redefine the boundaries of telehealth and personalized medicine for years to come.